Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Astena Holdings Co.,Ltd. ( (JP:8095) ).
Astena Holdings Co., Ltd. said it will receive a 458 million yen dividend from its consolidated subsidiary SPERA PHARMA, Inc., following a resolution passed at the subsidiary’s shareholders’ meeting on February 20, 2026. The dividend, scheduled to be received on February 24, 2026, underscores internal capital circulation within the group and highlights the subsidiary’s earnings capacity as a contributor to the parent’s financial flexibility.
The company will record the dividend as operating revenue in its non-consolidated financial statements for the fiscal year ending November 2026, which should support standalone profitability and balance sheet strength. However, because the payment comes from a consolidated subsidiary, it will have no effect on Astena Holdings’ consolidated financial results, limiting direct impact on group-level performance indicators while still signaling stable cash flows to stakeholders.
The most recent analyst rating on (JP:8095) stock is a Hold with a Yen493.00 price target. To see the full list of analyst forecasts on Astena Holdings Co.,Ltd. stock, see the JP:8095 Stock Forecast page.
More about Astena Holdings Co.,Ltd.
Astena Holdings Co., Ltd. is a Japan-based holding company listed on the TSE Prime Market under securities code 8095. Through its consolidated subsidiaries, including SPERA PHARMA, Inc., it operates in businesses related to pharmaceuticals and associated services, focusing on portfolio management and capital allocation within the group.
Average Trading Volume: 215,893
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen20.21B
For detailed information about 8095 stock, go to TipRanks’ Stock Analysis page.